An observational study in Chronic Myeloid Leukemia in Chronic Phase, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in China. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-01.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis — 9 open to participants now, 13 under way, 2 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Novartis.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 14th largest by planned enrollment of the 19 observational ones that give a count, is one of 4 that started in 2026, is one of 19 observational ones, reaches primary completion later than 7 of the 12 other live ones, and was the 89th registered.
895 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 105 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →9 of the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Australia, Brazil and 14 more countries
Ages 1–18
Novartis Pharmaceuticals · Sites in Germany
Ages 18–100
Novartis Pharmaceuticals · Sites in Saudi Arabia
Ages 18–99
Novartis Pharmaceuticals · Sites in France
Ages 18–99
Novartis Pharmaceuticals · Sites in Korea, Republic of
Ages 18–100
By country, each count listing its studies:
Of the 75 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 46 (61%) set no upper age limit and 19 (25%) stop at 75 or younger; 19 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 26 · Phase 3 20 · Phase 4 13
First in 1999; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 135 across 148 observational studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 84 across the 63 interventional studies, 400 across the 19 observational. Of the 73 that completed or were terminated, 35 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
5 of the studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06092879Novartis PharmaceuticalsAsciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France | 2026-12-15 |
| NCT06684964Novartis PharmaceuticalsRWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL) | 2026-12-30 |
| NCT07454850Novartis PharmaceuticalsA Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait | 2027-07-02 |
| NCT07681258Novartis PharmaceuticalsA Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region | 2027-09-01 |
| NCT04925479Novartis PharmaceuticalsStudy to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | 2027-09-03 |
Add all 5 to your calendar (.ics) → With an account.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, non-interventional real-world study designed to assess the efficacy and safety of asciminib in patients with newly diagnosed CML.The study uses a prospective data collection design to gather baseline, pre- and post-treatment, and long-term follow-up data, enabling a comprehensive assessment of asciminib's clinical benefits.
patients newly diagnosed with CML-CP and confirmed with Ph+ CML in medical records
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients eligible for inclusion in this study must meet all the following criteria:
Newly diagnosed with Ph+ CML-CP within 3 months before enrollment;
- The diagnosis documentation must include the type and quantitative level of the BCR-ABL1 transcript.
Patients scheduled to initiate treatment with asciminib;
- Patients beginning asciminib treatment must receive the first dose within 14 days of signing the ICF;
Exclusion Criteria:
Patients meeting any of the following criteria are not eligible for inclusion in this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Asciminib treatment
Cumulative rate of MMR
Cumulative rate of major molecular response (MMR) (BCR-ABL1 transcript level ≤ 0.1%) in patients receiving asciminib for 12 months
Time frame: Month 12
Cumulative rate of MMR
The cumulative MMR is defined as at least one BCR::ABL1 transcript level ≤ 0.1% during the follow-up period
Time frame: Month 3, Month 6, Month 9, Month 18 and Month 24
Cumulative rate of deep molecular response (DMR): MR4 and MR4.5
Cumulative rate of MR4 is defined as at least one BCR::ABL1 transcript level ≤ 0.01% during the follow-up period; Cumulative MR4.5 is defined as at least one BCR::ABL1 transcript level ≤0.0032% during the follow-up period
Time frame: Month 3, Month 6, Month 9, Month 12, Month 18, and Month 24
Cumulative rate of complete cytogenetic response (CCyR)
Cumulative CCyR is defined as at least one cytogenetic examination showing 0 Ph+ cells during the follow-up period
Time frame: Month 3, Month 6, and Month 12
Time to first MMR
Time to first MMR is defined as the time interval from baseline to the first occurrence of BCR::ABL1 transcript level ≤0.1% during the follow-up period
Time frame: 24 month follow up period
Time to first MR4 and MR4.5
Time to first MR4 is defined as the time interval from baseline to the first occurrence of BCR::ABL1 transcript level ≤0.01% during the follow-up period. Time to first MR4 is defined as the time interval from baseline to the first occurrence of BCR::ABL1 transcript level ≤0.0032% during the follow-up period
Time frame: 24 month follow up period
Time to first complete cytogenetic response (CCyR)
Time to first CCyR is defined as the time interval from baseline to the first occurrence of CCyRduring the follow-up period
Time frame: 24 month follow up period
Early molecular response (EMR) rate at 3 months
Proportion of patients achieving BCR::ABL1 transcript level ≤10% at M3
Time frame: Month 3
Complete hematologic response (CHR) rate
the proportion of patients achieving white blood cell count \< 10 × 109/L, platelet count \< 450 × 109/L, no immature myeloid cells in peripheral blood, peripheral blood basophil percentage \< 5%, absence of symptoms/signs of extramedullary involvement, and non-palpable spleen at M1, M2, and M3
Time frame: Month 1, Month 2, and Month 3
Rate of decline in BCR::ABL1 transcript levels
indirectly calculated from BCR::ABL1 transcript levels at baseline, M1, M2, M3, M6, M9, and M12; determined by BCR::ABL1 halving time
Time frame: Baseline, Month 1, Month 2, Month 3, Month 6, Month 9 and Month 12
Duration of MMR
Definition of duration: Duration = sum of "intervals"; Interval calculation method: the first visit at which a response is achieved (and previously unmeasured) within the interval is taken as the starting point, then evaluated sequentially in time order; the calculation stops upon encountering a visit that fails to meet the criterion; The duration is calculated as the time interval between the first and last visit at which the response was achieved; Missing visit data points during this period will be defaulted as achieving the response.
Time frame: 24 month follow up period
Duration of MR4 and MR4.5
Time frame: 24 month follow-up period
Event-Free survival (EFS) rate
Lack of efficacy: * Failure to achieve expected molecular response: failure to reach the molecular response milestones recommended by the ELN guidelines at prespecified time points; * Loss of molecular response: loss of confirmed MMR following achievement of MMR, or loss of CCyR. Disease progression: progression from the chronic phase to the accelerated phase or blast crisis. Death: fatal outcome due to any cause during the treatment period. Treatment discontinuation due to adverse events: permanent discontinuation caused by intolerable toxicity, serious adverse events, or other safety-related reasons associated with the study drug.
Time frame: Month 12 and Month 24
Progression-free survival (PFS) rate
Time frame: Month 12 and Month 24
Overall survival (OS) rate
Time frame: Month 12 and Month 24
Adverse events (AEs) and serious adverse events (SAEs) occurring during asciminib treatment
Time frame: 24 month follow-up period
Asciminib persistence rates
Time frame: Month 6, Month 12, and Month 24
Rates of asciminib treatment interruption/dose reduction and discontinuation due to AEs
Time frame: 24 month follow-up period
Proportion of patients requiring concomitant medications due to AEs
Time frame: 24 month follow-up period
Change in the simplified CML quality of life questionnaire from baseline
Time frame: Baseline, Month 12 and Month 24
Compliance following asciminib treatment
Medication possession ratio
Time frame: 24 month follow-up period
Concomitant medication use associated with AEs related to asciminib
Time frame: 24 month follow-up period
Hospitalization rate, outpatient visit rate, emergency department visit rate, and ICU admission rate related to CML treatment
Time frame: 24 month follow-up period
Gene mutation rate associated with asciminib treatment
Gene mutation rate associated with asciminib treatment; types and proportions of positive gene mutations identified via genetic testing.
Time frame: 24 month follow-up period
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Dec 2028, 34 months after the start.
Of 67 observational studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's planned 34 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →